$TEVA

2018 Q2 Form 10-Q Financial Statement

#000119312518236536 Filed on August 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $4.701B $5.720B
YoY Change -17.81% 13.54%
Cost Of Revenue $2.640B $2.865B
YoY Change -7.85% 32.58%
Gross Profit $2.033B $2.802B
YoY Change -27.44% -2.61%
Gross Profit Margin 43.25% 48.99%
Selling, General & Admin $1.026B $1.307B
YoY Change -21.5% 3.48%
% of Gross Profit 50.47% 46.65%
Research & Development $290.0M $469.0M
YoY Change -38.17% 25.07%
% of Gross Profit 14.26% 16.74%
Depreciation & Amortization $479.0M $577.0M
YoY Change -16.98% 86.13%
% of Gross Profit 23.56% 20.59%
Operating Expenses $1.316B $1.776B
YoY Change -25.9% 4.72%
Operating Profit -$14.00M -$5.740B
YoY Change -99.76% -586.03%
Interest Expense -$251.0M -$300.0M
YoY Change -16.33% 185.71%
% of Operating Profit
Other Income/Expense, Net -$236.0M -$238.0M
YoY Change -0.84%
Pretax Income -$250.0M -$5.978B
YoY Change -95.82% -2435.16%
Income Tax -$76.00M -$22.00M
% Of Pretax Income
Net Earnings -$176.0M -$5.970B
YoY Change -97.05% -2450.39%
Net Earnings / Revenue -3.74% -104.37%
Basic Earnings Per Share -$0.24 -$5.94
Diluted Earnings Per Share -$0.24 -$5.94
COMMON SHARES
Basic Shares Outstanding 1.018B shares 1.017B shares
Diluted Shares Outstanding 1.018B shares 1.017B shares

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.861B $599.0M
YoY Change 210.68% -91.42%
Cash & Equivalents $1.861B $599.0M
Short-Term Investments
Other Short-Term Assets $685.0M $1.544B
YoY Change -55.63% -25.23%
Inventory $4.971B $5.132B
Prepaid Expenses $1.104B
Receivables $6.061B $7.320B
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.71B $14.60B
YoY Change 0.79% -20.44%
LONG-TERM ASSETS
Property, Plant & Equipment $7.213B $8.043B
YoY Change -10.32% 20.17%
Goodwill $27.65B
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $806.0M $2.018B
YoY Change -60.06% -23.53%
Total Long-Term Assets $52.32B $71.76B
YoY Change -27.09% 81.32%
TOTAL ASSETS
Total Short-Term Assets $14.71B $14.60B
Total Long-Term Assets $52.32B $71.76B
Total Assets $67.03B $86.36B
YoY Change -22.38% 49.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.779B $2.278B
YoY Change -21.91% -40.91%
Accrued Expenses $2.922B $3.470B
YoY Change -15.79%
Deferred Revenue
YoY Change
Short-Term Debt $758.0M $981.0M
YoY Change -22.73%
Long-Term Debt Due $757.0M $265.0M
YoY Change 185.66% -90.8%
Total Short-Term Liabilities $14.22B $15.46B
YoY Change -8.04% 7.26%
LONG-TERM LIABILITIES
Long-Term Debt $28.95B $33.81B
YoY Change -14.37% 320.68%
Other Long-Term Liabilities $1.814B $2.038B
YoY Change -10.99% 50.63%
Total Long-Term Liabilities $33.45B $35.84B
YoY Change -6.69% 281.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.22B $15.46B
Total Long-Term Liabilities $33.45B $35.84B
Total Liabilities $47.66B $58.36B
YoY Change -18.33% 110.16%
SHAREHOLDERS EQUITY
Retained Earnings -$2.864B
YoY Change
Common Stock $54.00M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.149B
YoY Change
Treasury Stock Shares 106.0M shares
Shareholders Equity $17.94B $27.99B
YoY Change
Total Liabilities & Shareholders Equity $67.03B $86.36B
YoY Change -22.38% 49.09%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$176.0M -$5.970B
YoY Change -97.05% -2450.39%
Depreciation, Depletion And Amortization $479.0M $577.0M
YoY Change -16.98% 86.13%
Cash From Operating Activities $162.0M $741.0M
YoY Change -78.14% -23.05%
INVESTING ACTIVITIES
Capital Expenditures -$136.0M -$193.0M
YoY Change -29.53% 10.29%
Acquisitions
YoY Change
Other Investing Activities $542.0M -$199.0M
YoY Change -372.36% 298.0%
Cash From Investing Activities $406.0M -$392.0M
YoY Change -203.57% 74.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -56.00M -651.0M
YoY Change -91.4% -333.33%
NET CHANGE
Cash From Operating Activities 162.0M 741.0M
Cash From Investing Activities 406.0M -392.0M
Cash From Financing Activities -56.00M -651.0M
Net Change In Cash 512.0M -302.0M
YoY Change -269.54% -129.7%
FREE CASH FLOW
Cash From Operating Activities $162.0M $741.0M
Capital Expenditures -$136.0M -$193.0M
Free Cash Flow $298.0M $934.0M
YoY Change -68.09% -17.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6061000000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4748000000
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23426000000
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1779000000
CY2013Q3 teva Compensatory Damages And Penalties
CompensatoryDamagesAndPenalties
12400000
CY2013Q3 teva Annual Sales Of Lidoderm
AnnualSalesOfLidoderm
1400000000
CY2016Q3 teva Settlement Gain Position
SettlementGainPosition
41000000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
599000000
CY2017Q2 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
591000000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
14711000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1124000000 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
54000000
CY2018Q2 us-gaap Debt Current
DebtCurrent
1272000000
CY2018Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
27527000000
CY2005Q1 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
950000000
CY2008Q3 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
2300000000
CY2009Q1 teva Annual Sales At Time Of Settlement
AnnualSalesAtTimeOfSettlement
350000000
CY2013Q4 teva Annual Sales Of Lidoderm
AnnualSalesOfLidoderm
1200000000
CY2014Q1 teva Punitive Damages
PunitiveDamages
17900000
CY2015Q2 teva Modafinil Payment
ModafinilPayment
1200000000
CY2017Q2 teva Damages Assessment
DamagesAssessment
235500000
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1018282532 shares
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2289000000
CY2018Q2 us-gaap Assets
Assets
67030000000
CY2018Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
29000000
CY2018Q2 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
3183000000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1861000000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1861000000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2018Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
440000000
CY2018Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2668000000
CY2018Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
114000000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
674000000
CY2018Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
703000000
CY2018Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
1180000000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8940000000
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25152000000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16212000000
CY2018Q2 us-gaap Goodwill
Goodwill
27648000000
CY2018Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
18300000000
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
605000000
CY2018Q2 us-gaap Inventory Net
InventoryNet
4971000000
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2714000000
CY2018Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1432000000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14215000000
CY2018Q2 us-gaap Land
Land
374000000
CY2018Q2 us-gaap Liabilities
Liabilities
47662000000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67030000000
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33447000000
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
757000000
CY2018Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
28965000000
CY2018Q2 us-gaap Minority Interest
MinorityInterest
1430000000
CY2018Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
667000000
CY2018Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5737000000
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
685000000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
806000000
CY2018Q2 us-gaap Other Inventory In Transit
OtherInventoryInTransit
220000000
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1104000000
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1104000000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1814000000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7213000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
3760000000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3700000 shares
CY2018Q2 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2080000000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11961000000
CY2018Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
8300 Position
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2864000000
CY2018Q2 us-gaap Restructuring Reserve
RestructuringReserve
330000000
CY2018Q2 us-gaap Senior Notes
SeniorNotes
29815000000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19368000000
CY2018Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
106000000 shares
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
17938000000
CY2018Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
7310000000
CY2018Q2 us-gaap Treasury Stock Value
TreasuryStockValue
4149000000
CY2018Q2 teva Accrued Expenses
AccruedExpenses
2248000000
CY2018Q2 teva Sales Reserves And Allowances
SalesReservesAndAllowances
7138000000
CY2018Q2 teva Long Term Derivative Instruments
LongTermDerivativeInstruments
16000000
CY2018Q2 teva Long Term Debentures
LongTermDebentures
5000000
CY2018Q2 teva Modafinil Euro Sales
ModafinilEuroSales
46500000
CY2018Q2 teva Contingent Consideration Classified As Assets Or Liabilities Fair Value Disclosure
ContingentConsiderationClassifiedAsAssetsOrLiabilitiesFairValueDisclosure
-722000000
CY2018Q2 teva Payments On Account
PaymentsOnAccount
587000000
CY2018Q2 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
968000000
CY2018Q2 teva Long Term Debt Currency Portion Chf
LongTermDebtCurrencyPortionCHF
0.02 pure
CY2018Q2 teva Long Term Debt Currency Portion Eur
LongTermDebtCurrencyPortionEUR
0.33 pure
CY2018Q2 teva Long Term Debt Currency Portion Usd
LongTermDebtCurrencyPortionUSD
0.65 pure
CY2018Q2 teva Fair Value Assumption Possible Increase In Risk Free Interest Rate
FairValueAssumptionPossibleIncreaseInRiskFreeInterestRate
0.005 pure
CY2014Q4 teva Annual Sales Of Intuniv
AnnualSalesOfIntuniv
327000000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
988000000
CY2016Q4 teva Annual Sales Of Intuniv
AnnualSalesOfIntuniv
335000000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15382000000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7128000000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4505000000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23479000000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2069000000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1848000000
CY2017Q4 us-gaap Assets
Assets
70615000000
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
566000000
CY2017Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
3329000000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
963000000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
963000000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1124000000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
54000000
CY2017Q4 us-gaap Debt Current
DebtCurrent
3646000000
CY2017Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
26172000000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
574000000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3277000000
CY2017Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
106000000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
549000000
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
717000000
CY2017Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
254000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8331000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25971000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17640000000
CY2017Q4 us-gaap Goodwill
Goodwill
28414000000
CY2017Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
18000000000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
597000000
CY2017Q4 us-gaap Inventory Net
InventoryNet
4924000000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2689000000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1454000000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17921000000
CY2017Q4 us-gaap Land
Land
390000000
CY2017Q4 us-gaap Liabilities
Liabilities
51870000000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70615000000
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
38000000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33949000000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2880000000
CY2017Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
28829000000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
1386000000
CY2017Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
1200000000
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5809000000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
701000000
CY2017Q4 us-gaap Notes Payable
NotesPayable
3426000000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
932000000
CY2017Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
184000000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1100000000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
724000000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1843000000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7673000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
3631000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3700000 shares
CY2017Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2016000000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12178000000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3808000000
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
311000000
CY2017Q4 us-gaap Senior Notes
SeniorNotes
28367000000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18745000000
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
107000000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17359000000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
8077000000
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4149000000
CY2017Q4 teva Accrued Expenses
AccruedExpenses
3014000000
CY2017Q4 teva Sales Reserves And Allowances
SalesReservesAndAllowances
7881000000
CY2017Q4 teva Long Term Derivative Instruments
LongTermDerivativeInstruments
2000000
CY2017Q4 teva Long Term Debentures
LongTermDebentures
20000000
CY2017Q4 teva Contingent Consideration Classified As Assets Or Liabilities Fair Value Disclosure
ContingentConsiderationClassifiedAsAssetsOrLiabilitiesFairValueDisclosure
-735000000
CY2017Q4 teva Payments On Account
PaymentsOnAccount
634000000
CY2017Q3 teva Annual Sales Of Effexor
AnnualSalesOfEffexor
2600000000
CY2015Q3 teva Annual Sales Of Aggrenox
AnnualSalesOfAggrenox
455000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59000000 shares
us-gaap Adjustment For Amortization
AdjustmentForAmortization
731000000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
159000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
731000000
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
48000000
us-gaap Cash Flows Between Transferor And Transferee Beneficial Interest
CashFlowsBetweenTransferorAndTransfereeBeneficialInterest
640000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
64000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-389000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4566000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4502000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5676000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1057000000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.37
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29000000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.37
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-344000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6100000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
729000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
156000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5290000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000000
us-gaap Gross Profit
GrossProfit
5694000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
54000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
1351000000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-34000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5455000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-445000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1430000000
us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-13000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
827000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2419000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
571000000
us-gaap Net Income Loss
NetIncomeLoss
-5325000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
69000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
872000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4845000000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
37000000
us-gaap Other Income
OtherIncome
96000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
130000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
691000000
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
38000000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
130000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
395000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
286000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
521000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-21000000
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-1477000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1485000000
us-gaap Profit Loss
ProfitLoss
-5329000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
583000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
901000000
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
211000000
us-gaap Restructuring Charges
RestructuringCharges
228000000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11370000000
us-gaap Share Based Compensation
ShareBasedCompensation
75000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1902000000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1016000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1016000000 shares
teva Other Operating Income Net
OtherOperatingIncomeNet
13000000
teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
161000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
13000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
65000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
14000000
teva Gain From Currency Swap
GainFromCurrencySwap
4000000
teva Interest Rate Swap Gain
InterestRateSwapGain
3000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-127000000
teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
49000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
66000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
659000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
344000000
teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
26000000
teva Venezuela Impairment Of Net Monetary Assets
VenezuelaImpairmentOfNetMonetaryAssets
18000000
teva Inventory Step Up
InventoryStepUp
67000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
87000000
teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
83000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
659000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65000000 shares
us-gaap Adjustment For Amortization
AdjustmentForAmortization
612000000
dei Amendment Flag
AmendmentFlag
false
us-gaap Asset Impairment Charges
AssetImpairmentCharges
980000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
611000000
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
2000000
us-gaap Cash Flows Between Transferor And Transferee Beneficial Interest
CashFlowsBetweenTransferorAndTransfereeBeneficialInterest
970000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
46000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
898000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
504000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
550000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5357000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
986000000
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
493000000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.80
dei Entity Central Index Key
EntityCentralIndexKey
0000818686
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-58000000
dei Entity Registrant Name
EntityRegistrantName
TEVA PHARMACEUTICAL INDUSTRIES LTD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.80
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
9000000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
83000000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1300000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
300000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
645000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
980000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1004000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-66000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-30000000
us-gaap Gross Profit
GrossProfit
4409000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
727000000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
94000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
1268000000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-44000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
814000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-507000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1445000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2147000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1658000000
us-gaap Net Income Loss
NetIncomeLoss
944000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
24000000
us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-1000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-418000000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
-56000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-472000000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 Segment
us-gaap Operating Income Loss
OperatingIncomeLoss
1511000000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000000
us-gaap Other Income
OtherIncome
299000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
130000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
12000000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
11000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4435000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-10000000
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-261000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
841000000
us-gaap Profit Loss
ProfitLoss
968000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6289000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
607000000
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
51000000
us-gaap Restructuring Charges
RestructuringCharges
354000000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9766000000
us-gaap Share Based Compensation
ShareBasedCompensation
77000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1481000000
teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
22000000
teva Valuation Allowances And Reserves Foreign Currency Translation
ValuationAllowancesAndReservesForeignCurrencyTranslation
-34000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
142000000
teva Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Revaluation Of Debt Securities
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisRevaluationOfDebtSecurities
-1000000
teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
194000000
teva Number Of Lawsuits Filed
NumberOfLawsuitsFiled
1000 Lawsuit
teva Restructuring Plan Period
RestructuringPlanPeriod
P2Y
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
253000000
dei Trading Symbol
TradingSymbol
TEVA
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1020000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1018000000 shares
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
10850000000
teva Other Operating Income Net
OtherOperatingIncomeNet
13000000
teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
55000000
teva Finite Lived Intangible Assets Transferred From In Process Research And Development To Product Rights
FiniteLivedIntangibleAssetsTransferredFromInProcessResearchAndDevelopmentToProductRights
103000000
teva Utilization And Other
UtilizationAndOther
335000000
teva Transactions Termination Loss Settled
TransactionsTerminationLossSettled
242000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
14000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
88000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
56000000
teva Gain From Currency Swap
GainFromCurrencySwap
16000000
teva Interest Rate Swap Gain
InterestRateSwapGain
3000000
teva Annual Sales Of Namenda
AnnualSalesOfNamenda
1400000000
teva Compensatory Damages For State Of Illinois
CompensatoryDamagesForStateOfIllinois
90000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-489000000
teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
5000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
31000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
1422000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
-1258000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
1422000000
teva Valuation Allowances And Reserves Related To Current Period Sales
ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
10168000000
teva Valuation Allowances And Reserves Related To Prior Period Sales
ValuationAllowancesAndReservesRelatedToPriorPeriodSales
-51000000
CY2009Q4 teva Annual Sales Of Namenda
AnnualSalesOfNamenda
1100000000
CY2017Q4 teva Brand Sales Of Palonosetron Iv Product
BrandSalesOfPalonosetronIvProduct
459000000
CY2005Q2 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
416000000
CY2013Q3 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
1100000000
CY2008Q3 teva Annual Sales Of Aggrenox
AnnualSalesOfAggrenox
340000000
CY2012Q3 teva Annual Sales Of Actos
AnnualSalesOfActos
2800000000
CY2012Q3 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
430000000
CY2010Q4 teva Annual Sales Of Actos
AnnualSalesOfActos
3700000000
CY2010Q4 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
500000000
CY2014Q4 teva Nexium Settlement Payment
NexiumSettlementPayment
24000000
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2017 teva Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit
112000000
CY2015Q1 teva Annual Sales Of Velcade
AnnualSalesOfVelcade
94000000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59000000 shares
CY2017Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
411000000
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
410000000
CY2017Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
25000000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2000000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5656000000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5658000000
CY2017Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2865000000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.94
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.94
CY2017Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6100000000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
363000000
CY2017Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
145000000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5978000000
CY2017Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-14000000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000000
CY2017Q2 us-gaap Gross Profit
GrossProfit
2855000000
CY2017Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
52000000
CY2017Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
324000000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6035000000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-238000000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5970000000
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
312000000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
77000000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
406000000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5740000000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000000
CY2017Q2 us-gaap Other Income
OtherIncome
24000000
CY2017Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
65000000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-5970000000
CY2017Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
469000000
CY2017Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
106000000
CY2017Q2 us-gaap Restructuring Charges
RestructuringCharges
98000000
CY2017Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5720000000
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
944000000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1017000000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1017000000 shares
CY2017Q2 teva Other Operating Income Net
OtherOperatingIncomeNet
16000000
CY2017Q2 teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
140000000
CY2017Q2 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
6000000
CY2017Q2 teva Gain From Currency Swap
GainFromCurrencySwap
4000000
CY2017Q2 teva Interest Rate Swap Gain
InterestRateSwapGain
1000000
CY2017Q2 teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
15000000
CY2017Q2 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
11000000
CY2017Q2 teva Impairment And Restructuring
ImpairmentAndRestructuring
419000000
CY2017Q2 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
324000000
CY2017Q2 teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
21000000
CY2017Q2 teva Inventory Step Up
InventoryStepUp
3000000
CY2017Q2 teva Other Unallocated Amounts
OtherUnallocatedAmounts
44000000
CY2017Q2 teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
8000000
CY2017Q2 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
419000000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
63000000 shares
CY2018Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
302000000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
301000000
CY2018Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
2000000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-51000000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-729000000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-780000000
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2640000000
CY2018Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.30 pure
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2018Q2 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2018Q2 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-10000000
CY2018Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
120000000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
316000000
CY2018Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
548000000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-250000000
CY2018Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8000000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-76000000
CY2018Q2 us-gaap Gross Profit
GrossProfit
2061000000
CY2018Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
520000000
CY2018Q2 us-gaap Inventory Recall Expense
InventoryRecallExpense
41000000
CY2018Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
20000000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-241000000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-236000000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-176000000
CY2018Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
10000000
CY2018Q2 us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-2000000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-614000000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
-100000000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-711000000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14000000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000000
CY2018Q2 us-gaap Other Income
OtherIncome
96000000
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
65000000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-166000000
CY2018Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
290000000
CY2018Q2 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
30000000
CY2018Q2 us-gaap Restructuring Charges
RestructuringCharges
107000000
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4701000000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
710000000
CY2018Q2 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
28000000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1018000000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1018000000 shares
CY2018Q2 teva Other Operating Income Net
OtherOperatingIncomeNet
10000000
CY2018Q2 teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
47000000
CY2018Q2 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
7000000
CY2018Q2 teva Gain From Currency Swap
GainFromCurrencySwap
9000000
CY2018Q2 teva Interest Rate Swap Gain
InterestRateSwapGain
2000000
CY2018Q2 teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
4000000
CY2018Q2 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
11000000
CY2018Q2 teva Impairment And Restructuring
ImpairmentAndRestructuring
715000000
CY2018Q2 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
20000000
CY2018Q2 teva Other Unallocated Amounts
OtherUnallocatedAmounts
81000000
CY2018Q2 teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
95000000
CY2018Q2 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
715000000

Files In Submission

Name View Source Status
0001193125-18-236536-index-headers.html Edgar Link pending
0001193125-18-236536-index.html Edgar Link pending
0001193125-18-236536.txt Edgar Link pending
0001193125-18-236536-xbrl.zip Edgar Link pending
d581454d10q.htm Edgar Link pending
d581454dex311.htm Edgar Link pending
d581454dex312.htm Edgar Link pending
d581454dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
teva-20180630.xml Edgar Link completed
teva-20180630.xsd Edgar Link pending
teva-20180630_cal.xml Edgar Link unprocessable
teva-20180630_def.xml Edgar Link unprocessable
teva-20180630_lab.xml Edgar Link unprocessable
teva-20180630_pre.xml Edgar Link unprocessable